ResMed said net revenue for the year ended June 30, 2025 increased to $5,146.3 million from $4,685.3 million, an increase of 10%, and net income was $1,400.7 million, or $9.51 per diluted share.

10-KAnnual reportFiled Aug 8, 2025Period of report Jun 30, 2025Summary published (UTC) Oct 11, 2026

Key points

AI summary

ResMed said net revenue for the year ended June 30, 2025 increased to $5,146.3 million from $4,685.3 million, an increase of 10%, and net income was $1,400.7 million, or $9.51 per diluted share.
The company said gross profit for the year increased to $3,055.0 million, an increase of 15%, and gross margin was 59.4% compared with 56.7% in the prior year. It cited procurement, manufacturing and logistics efficiencies, $14.3 million of combined field safety notification expenses recognized in the prior year, and a reduction in amortization of acquired intangibles as factors.
ResMed said operating cash flow for the year increased to $1,751.6 million, an increase of $350.3 million, and included $124.4 million of income tax refunds and associated interest and penalties. As of June 30, 2025, cash and cash equivalents totaled $1,209.5 million and total debt outstanding was $670.0 million.
The company said cash used in financing activities for the year was $606.3 million, it repurchased $300.0 million of treasury stock, and it paid cash dividends of $2.12 per common share, totaling $310.9 million. On July 31, 2025, the board declared a cash dividend of $0.60 per common share.

Key figures

Fiscal year ended June 30, 2025

Revenue: $5.1B
Operating income: $1.7B
Net income: $1.4B
EPS: $9.51
Gross profit: $3.1B
Operating cash flow: $1.8B

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Annual net revenue and net income

ResMed said net revenue for the year ended June 30, 2025 increased to $5,146.3 million from $4,685.3 million, an increase of 10%, and net income was $1,400.7 million, or $9.51 per diluted share.

Source · Based on the MD&A text of the filing

Gross margin and factors cited by the company

The company said gross profit for the year increased to $3,055.0 million, an increase of 15%, and gross margin was 59.4% compared with 56.7% in the prior year. It cited procurement, manufacturing and logistics efficiencies, $14.3 million of combined field safety notification expenses recognized in the prior year, and a reduction in amortization of acquired intangibles as factors.

Source · Based on the MD&A text of the filing

Operating cash flow, liquidity and debt

ResMed said operating cash flow for the year increased to $1,751.6 million, an increase of $350.3 million, and included $124.4 million of income tax refunds and associated interest and penalties. As of June 30, 2025, cash and cash equivalents totaled $1,209.5 million and total debt outstanding was $670.0 million.

Source · Based on the MD&A text of the filing

Treasury stock repurchases and dividends

The company said cash used in financing activities for the year was $606.3 million, it repurchased $300.0 million of treasury stock, and it paid cash dividends of $2.12 per common share, totaling $310.9 million. On July 31, 2025, the board declared a cash dividend of $0.60 per common share.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.